Kornimate/medical-research-clean huggingface dataset:
comparing the accuracy of different blood glucose monitoring systems (cgm and fgm)

Conditions: Type 2 Diabetes

Summary: to compare the accuracy of different blood glucose monitoring systems (cgm and fgm) in diabetic patients with insufficient islet function.

to compare the accuracy of different blood glucose monitoring systems (cgm and fgm) in diabetic patients with insufficient islet function with venous blood glucose (including fgm early, middle and late, pre-and post-meal, high and low blood glucose).

Eligibility criteria:
inclusion criteria: * volunteer to participate and be able to sign informed consent prior to the trial. * patients with type 2 diabetes or type 1 diabetes, aged 18-80 years old. * no acute complications such as diabetic ketoacidosis, diabetic hyperosmolar syndrome, etc. * subjects are able and willing to monitor peripheral blood sugar and regularity of diet and exercise. exclusion criteria: * patients with insulin allergy. * impaired liver and kidney function with alt 2.5 times higher than the upper limit of normal value; serum creatinine was 1.3 times higher than the upper limit of normal. * drug abuse and alcohol dependence in the past 5 years. * systemic hormone therapy was used in the last three months. * patients with poor compliance and irregular diet and exercise. * patients with pregnancy, lactation or pregnancy intention. * any other obvious conditions or associated diseases determined by the researcher: such as severe cardiopulmonary diseases, endocrine diseases, neurological diseases, tumors and other diseases, other pancreatic diseases, history of mental diseases.

Keywords: fgm cgm
knowledge, attitude and practice regarding caries risk assessment for children and adults among dental residents

Conditions: Dental Caries

Summary: evaluation of knowledge, practice and attitude regarding caries risk assessment for children and adults among dental residents in faculty of dentistry, cairo university.

dental caries is a dynamic and multifactorial process. occurrence of dental caries is affected by several factors including quantity and composition of saliva, oral microflora and patient-related parameters including general health and lifestyle, such as the use of fluoride-containing toothpastes and diet. caries risk is defined as the probability of developing caries in the future. the incidence of the disease can be either primary (new caries lesions) or secondary (progression of lesion or reactivation of caries lesions). caries risk assessment (cra) is important for the successful application of a minimum intervention dentistry philosophy in the management of dental caries. patients, with active caries at the time of visit, need the cra to identify the factors that are most likely to progress in the disease process. the cra is one of the methods for managing the caries of patients. riley et al. showed that the anti-caries agents were widely used in dental clinics, while the cra was performed by a few dental clinics. in a study of gaskin et al., 63.5% of subjects agreed with the use of minimal intervention dentistry. in a study of shah et al., 36% of dentists accepted the use of restorative materials and cra-based methods, and 15.5% also strongly agreed with cra for all patients. in a study by rayapudi and usha, 81% of participants agreed with cra in patients. in a study by riley et al. about the use of cra by dentists in children, 73% of dentists reported having cras for people aged 6 to 18 years. in another study by riley et al., 69% of dentists performed cra for patients, and 57% of dentists who performed cra had considered an individualized caries prevention programs for their patients. hurlbutt et al. showed that caries management by the cra is an example of patient care that has the best practice rather than traditional therapies. afshar et al. claimed that the cra is a conservative approach that can prevent waste of time, energy and finances. evaluating the management of the results of illness in certain periods of time leads to less dental tissues wasting. people's knowledge of cra in patients leads to more conservative treatment. due to limited studies in this field and the absence of data about using cra in egypt, especially on dental residents, this study was conducted to evaluate the knowledge, attitude and practice regarding caries risk assessment among pediatric and conservative dental residents in faculty of oral and dental medicine, cairo university.

Eligibility criteria:
inclusion criteria: * pediatric and conservative dental residents in faculty of dentistry, cairo university. completing at least 3 months residency program in one of the departments exclusion criteria: * participants who refuse to participate.
4-repeat tauopathy neuroimaging initiative - cycle 2

Conditions: Corticobasal Degeneration (CBD); Corticobasal Syndrome (CBS); Cortical-basal Ganglionic Degeneration (CBGD); Progressive Supranuclear Palsy (PSP); Nonfluent Variant Primary Progressive Aphasia (nfvPPA); Oligosymptomatic/Variant Progressive Supranuclear Palsy (o/vPSP)

Summary: the goal of this study is to identify the most reliable methods of analysis for tracking cbd, psp, and o/vpsp over time. the results from this study may be used in the future to calculate statistical power for clinical drug trials. the study will also provide information about the relative value of novel imaging techniques for diagnosis, as well as the value of imaging techniques versus testing of blood, urine, and cerebrospinal fluid (csf) 'biomarkers'.


Eligibility criteria:
inclusion criteria: * no known history of neurological disease, or meet criteria for one of the following: corticobasal syndrome or degeneration (cbs or cbd); progressive supranuclear palsy (psp); or oligo- or variant- progressive supranuclear palsy (o/vpsp) * needs a reliable study partner who has frequent contact with the participant, who is available to provide information about the participant, and who can accompany the participant to research visits as needed * must be willing and able to undergo testing procedures, which include longitudinal follow-up visits * must be able to walk five steps with minimal assistance exclusion criteria: * significant neurological disease other than cbd, psp, or a variant psp syndrome. * presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, or metal fragments or metal objects in the eyes, skin, or body * in the site investigator's opinion, inability to complete sufficient key study procedures, or some other equivalent assessment of impairment

Keywords: cbd cbs cbgd psp nfvppa opsp vpsp o/vpsp corticobasal degeneration corticobasal syndrome cortocal-basal ganglionic degeneration progressive supranuclear palsy nonfluent variant primary progressive aphasia oligosymptomatic progressive supranuclear palsy variant progressive supranuclear palsy biomarker neuroimaging mri pet tau oculomotor retinal imaging
nutritional study to determine the effect of fish oil on atopic dermatitis

Conditions: Atopic Dermatitis

Summary: atopic dermatitis is associated with pronounced changes in the lipid composition in the skin. the lipid changes are influenced by and contributing to both the inflammatory circuit and the impaired barrier as well as changes in the skin microbiome this nutritional study will investigate the effect of long-chain monounsaturated fatty acid cetoleic acid on atoptic dermatitis. earlier studies have shown a anti-inflammatory effect of celoteic acid.

women and men will be recruited to a placebo or a cetoleic-rich fish oil group and be examined for the effect on atopic dermatitis before, during and after the study period.

Eligibility criteria:
inclusion criteria: * women and men 18-80 years of age. * diagnosed with active mild to moderate atopic dermatitis with an easi of 1.1- 21.0. * willing to refrain from oil supplements (omega-3, borage, evening primrose, etc.) for 1 month before study begin (washout) and during the study * willing to take the study supplement for 6 months exclusion criteria: * known allergy to fish products * subjects known to be pregnant or breast feeding * subjects perceiving systemically administered medication for ad (other than topical) * subjects with auto-immune diseases (except asthma and seasonal/perennial rhinitis) * subjects with a diagnosis of other skin diseases

Keywords: cetoleic acid lc-mufa ezcema nutritional study
safety and effectiveness of the globe® pulsed field system for treating patients with symptomatic paroxysmal or persistent atrial fibrillation

Conditions: Paroxysmal Atrial Fibrillation; Persistent Atrial Fibrillation

Summary: this study will evaluate the safety and effectiveness of the globe® pulsed field system for treating patients with symptomatic paroxysmal or persistent atrial fibrillation (af).


Eligibility criteria:
key inclusion criteria: * a diagnosis of recurrent symptomatic paroxysmal or persistent af * failure or intolerance of at least one antiarrhythmic drug (aad) class i or iii key exclusion criteria: * long-standing persistent af (sustained \>12 months) * atrial fibrillation secondary to a reversible cause or of non-cardiac origin * history of thromboembolic events within the past six months * myocardial infarction (mi)/percutaneous coronary intervention (pci) within the last three months * any cardiac surgery within the previous six months * prior left atrial ablation or surgical procedure * presence of an implanted cardiac device * body mass index (bmi) \>40 kg/m\^2 * left ventricular ejection fraction (lvef) \<35% * anterior-posterior left atrial (la) diameter \>55mm

Keywords: pulsed field ablation irreversible electroporation
clinical phenotypic characteristics of sc26a4

Conditions: Hearing Loss; Pendred Syndrome

Summary: the presence or absence of sc26a4, whether combined with mondini malformation, and patient age, are important factors affecting the degree of hearing loss in the chinese population.

to summarize the solute carrier family 26 member 4 (slc26a4) mutation and clinical phenotypic characteristics of pendred syndrome/nonsyndromic enlarged vestibular aqueduct (ps/nseva) patients and provide evidence supporting the clinical diagnosis and genetic counseling of patients with ps/nseva. a retrospective cohort study for the chinese population is needed.

Eligibility criteria:
inclusion criteria: 1. patients with enlarged vestibular aqueduct; 2. patients with hearing loss; 3. patients with results of slc26a4 sequencing; exclusion criteria: subjects will be excluded from this study if any of the following are present: 1. audiometric data is incomplete 2. incomplete basic information 3. patients who did not undergo hrct
the significance of peripheral input

Conditions: Neuropathic Pain

Summary: the investigators want to examine trigger point injections of local anesthetics, in patients with post operative neuropathic pain, determine changes in sensory disturbances such as allodynia, hyperalgesia and thermal sensitivity and examine whether trigger point injections will attenuate pain in rest and activity.

the presence of cutaneous trigger points in the surgical incision of patients with post-surgery pain has been shown in our pain clinic, all patients have persistent pain for more than 3 month and different sensory disturbances. examinations with trigger point injections of local anesthetics have been used to determine the influence of peripheral changes and the significance of afferent input on persistent post-surgery neuropathic pain. in the present study the investigators will document the influence of cutaneous trigger point injections for both subjective pain experience and objective findings in the area such as allodynia, hyperalgesia and thermal sensitivity. the investigators expect reduction in spontaneous pain intensity and de-crease in peripheral sensory disturbances and will determine the significance of peripheral input in persistent neuropathic pain. the investigators aim to investigate whether injection of local anesthesia into trigger points compared with placebo (saline) injection will attenuate pain and normalize abnormal sensations, such as hyperalgesia and allodynia. the investigators believe this to be an important investigation to understand the mechanisms behind chronic post-surgery pain.

Eligibility criteria:
inclusion criteria: * age \> 18 years old * patients with chronic pain (daily vas pain scores \>30 mm) for at least 3 months after knee, shoulder or foot surgery * patients with at least one identifiable trigger point in relation to incision from the knee, shoulder or foot surgery. a trigger point is defined as an ar-ea in relation to the incision from surgery, in which a light pressure from a cotton pin radiate pain to the nearby area, and exudes a motor reflex causing withdrawal of the leg * a written informed consent to participate in the study after having fully understood the contents of the protocol and restrictions exclusion criteria: * patients who cannot cooperate * patients who cannot understand or speak danish. * patients with allergy to the drugs used in the study * patients in treatment with vitamin k antagonists. * patients with other pain conditions * patients with diabetes

Keywords: peripheral input trigger point injection post operative pain
iguratimod as treatment for refractory lupus nephritis

Conditions: Lupus Nephritis

Summary: this study is to evaluate the efficacy and safety of a novel chemical synthetic agent iguratimod as treatment of refractory lupus nephritis. all subjects should have at least one failed immunosuppressive treatment and suffer active nephritis at the screening stage. the study period is 52 week. all the subject will receive therapy of iguratimod combined with steroids.


Eligibility criteria:
inclusion criteria: * active lupus nephritis: fulfill acr classification criteria (2009) for sle proteinuria ≥1g/24h at screening stage experience at least one failed therapy within one year before screening, including but not limit to cyclophosphamide, methotrexate, azathioprine, mycophenolate mofetil, cyclosporin, tacrolimus and leflunomide. the regime can be monotherapy or combination. any regime should be at least applied for six months. * body weight ≥40kg * sle-2k score ≥8 * agreement of contraception * informed consent obtained exclusion criteria: * active severe sle-driven renal disease or unstable renal disease at screening * active severe or unstable neuropsychiatric sle * clinically significant active infection including ongoing and chronic infections * history of human immunodeficiency virus (hiv) * confirmed positive tests for hepatitis b or positive test for hepatitis c * active tuberculosis * live or attenuated vaccine within 4 weeks prior to screening * subjects with significant hematologic abnormalities * abnormal liver function test at screening (alt, ast or total bilirubin over 2 fold of upper normal level * history of peptic ulcer or gi bleeding; treatment with warfarin or other anticoagulants within last 14 days
the safety and pharmacokinetic/pharmacodynamic study of ckd-841 in postmenopausal female, phase 1

Conditions: Early Puberty

Summary: a randomized, single-blinded, parallel design phase i clinical trial to investigate the safety and pharmacokinetics/pharmacodynamics of ckd-841 a-1, ckd-841 d or leuplin inj. after subcutaneous injection in postmenopausal female

to investigate the safety and pharmacokinetics/pharmacodynamics of ckd-841 a-1, ckd-841 d or leuplin inj. 3.75 mg after subcutaneous injection in postmenopausal female

Eligibility criteria:
inclusion criteria: * healthy menopausal female * β-hcg is negative at screening and before administration of investigational drug * infertility by sterilization operation before 5 months from screening excluding ovarian cancer, uterine cancer etc. * bwt ≥ 50kg and body mass index (bmi) ≥ 18.5 and \< 28.0 exclusion criteria: * history or current condition of disease related to hepato-biliary system, renal system, nervous system, mental illness, immune system, respiratory system, endocrine system, hemato-oncology, circulatory system, musculoskeletal system or except for that, significant clinical disease * uncontrolled diabetes mellitus in the last three months * pregnancy or breast feeding * history of taking medicine such as leuprorelin acetate or similar affiliation drug within 12 weeks before administration of investigational drug * has hypersensitivity to the active ingredient or excipients or same affiliation drug of the investigational drug, hypersensitivity of a medicine contained gelatin especially

Keywords: ckd-841 postmenopausal leuplin
cp-751,871 treatment for patients with multiple myeloma

Conditions: Multiple Myeloma

Summary: this study represents the first-in-human study for cp-751,871. the study aimed to define the safety, tolerability, and maximum tolerated dose of cp-751,871 in patients with multiple myeloma through a dose escalation design.


Eligibility criteria:
inclusion criteria: * previously treated multiple myeloma with a quantifiable serum (m spike ≥ 1 g/dl) and/or urine (≥ 200 mg/24-hr) paraprotein * adequate bone marrow, renal, liver and cardiac function * eastern cooperative oncology group \[ecog\] performance status less than or equal to 2 exclusion criteria: * prior allogeneic stem cell transplant (allosct) * myelosuppressive chemotherapy or immunotherapy within 3 weeks prior to treatment with cp-751,871 * prior organ allograft * concurrent use of insulin, oral hypoglycemic medication, growth hormone (gh), or growth hormone inhibitors * female patients who are pregnant or lactating

Keywords: igf-1r inhibitor cp-751871 multiple myeloma
seminal fluid's changes over 20 years

Conditions: Oligospermia

Summary: this is a cohort study including all the first seminal exams performed at the fertility center, humanitas research hospital (rozzano, milan) between january 1998 and december 2018.

the objective of this study is to evaluate retrospectively different changes of tpmsc during last 20 years in male population who underwent a seminal exam in our center

Eligibility criteria:
inclusion criteria: * male over 18 years old exclusion criteria: * error in birth or exam date or age under 18, * abstinence days \ 6, volume missing o \> 10 ml, * spermatozoa number/ ml missing o \>220 x106, * normal forms missing, * progressive motility missing
the prevalence of autoimmune antibodies in patients with type 2 diabetes managed by endocrinology vs. primary care

Conditions: Type 2 Diabetes

Summary: the purpose of this study is to assess the levels of autoimmune markers of diabetes in those with a type 2 diabetes diagnosis.

autoimmune markers can appear when the body uses its natural defense system to mistakenly attack the patient's own cells because it cannot tell the difference between the patient and foreign cells. the study investigators want to determine if there are any differences in these marker levels when comparing patients who are managed by their primary care provider and patients managed by endocrinology. patients will be asked to come in for a blood draw. this sample will be used for autoimmune antibody testing. an antibody is a protein in the blood that is made to find and respond to a specific antigen. an antigen is something that triggers the body to have an immune response. patient participation in the research study will last for the duration of one visit to the clinic for informed consent and a blood draw. the clinical implications of detecting this type of diabetes can be profound, as it can identify patients who are at risk of becoming insulin dependent in the near future, and therefore may require a change in diabetes management to avoid adverse outcomes. in addition, identifying these patients may also open up the door for treatments directed at stopping the complete autoimmune destruction of insulin producing cells, potentially delaying or avoiding the need for insulin dependency. the study team presumes that autoimmune markers of diabetes will be detected in patients with a diagnosis of type 2 diabetes and the prevalence of these markers will be higher among patients managed by endocrinology. the population of patients found to have detectable autoimmune markers of diabetes will differ from the population of patients without these markers. the population of patients managed by endocrinology that are found to have detectable autoimmune markers of diabetes will differ from the population of patients managed by primary care. the population of patients with more than 1 autoimmune antibody are more likely to require insulin therapy.

Eligibility criteria:
inclusion criteria: * language: english * age: ≥ 18 * type 2 diabetes * ability to provide informed consent before any trial-related activities. trial-related activities are any procedure that would not have been performed during normal management of the subject. exclusion criteria: * patients with a diagnosis of t1d or lada in their problem list * patients with an encounter diagnosis for t1d or lada * mental incapacity or language barrier (non-english speaking)
evaluate 4 different formulations of meningococcal serogroups a,c,w-135,y conjugate vaccine when given as 1 dose to healthy subjects aged 15-19 yrs

Conditions: Infections, Meningococcal

Summary: the purpose of this study is to evaluate the immunogenicity, safety and reactogenicity of one dose of four different formulations of the menacwy conjugate vaccine when given to healthy subjects aged 15-19 years. the selection of the best formulation will be based on data obtained up to one month after the vaccine dose.

the study is open. however, the 4 different formulations of gsk's menacwy conjugate vaccine will be administered in a double-blind manner. mencevax™ acwy vaccine will serve as active control. subjects will receive one vaccine dose only (gsk's menacwy conjugate vaccine or mencevax™ acwy vaccine), and will have 2 blood samples taken, before and one month after vaccination.

Eligibility criteria:
inclusion criteria: * healthy male or female between, and including, 15 and 19 years of age at the time of vaccination. * subject with previously completed routine childhood vaccinations to the best of his/her knowledge or his/her parents'/guardians' knowledge. * female subjects should be of non-childbearing potential. exclusion criteria: * previous vaccination against or history of or exposure within previous 12 months to meningococcal serogroup a, c, w-135 or y disease. * administration of a tetanus vaccine within 6 months before study vaccination. * any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (hiv) infection. * a family history of congenital or hereditary immunodeficiency. * history of any neurologic disorders or seizures.

Keywords: meningococcal serogroups a, c, w-135, y disease